Security key
09090D301
BiomX Inc. - Common Stock, $0.0001 par value (PHGE)
CUSIP: 09090D301
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / Common Stock, $0.0001 par value
- Total 13F shares
- 13,299,821
- Total 13F value
- $7,390,820
- Share change
- +3,339,175
- SEC-reported price per share
- $0.56
- Number of holders
- 18
- Value change
- +$1,849,949
- Number of buys
- 10
- Number of sells
- 4
- Shares outstanding
- 1,527,040
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
18
Top holders
10
PHGE full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2025
Previous quarter: Q4 2024
BiomX Inc. SEC filings
BiomX Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 09090D301
Recent filing periods:
Ownership snapshot
Top reported holders of PHGE - BiomX Inc. - Common Stock, $0.0001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Cystic Fibrosis Foundation
Disclosed value leader
Cystic Fibrosis Foundation
Comparable rows
15/15
Latest evidence
31 Mar 2025
3/4/5
13D/G
13F
Lead comparable stake: 10%
13D/G row: Cystic Fibrosis Foundation
Showing 1-6 of 15 holder rows.
Quick read
Cystic Fibrosis Foundation leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Cystic Fibrosis Foundation's linked filing trail.
Comparable ownership
Top 5
Cystic Fibrosis Foundation
10%
Nantahala Capital Management, LLC
10%
ORBIMED ADVISORS LLC
117%
DEERFIELD MANAGEMENT COMPANY, L.P.
117%
Ikarian Capital, LLC
58%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Cystic Fibrosis Foundation |
3/4/5
13D/G
10%+ Owner
|
10%
from 13D/G
|
$1,663,688
11,131,426 shares
mixed-class rows
|
— | 26 Feb 2025 |
| Nantahala Capital Management, LLC |
13D/G
13F
Company
|
10%
|
$1,496,518
2,494,197 shares
|
+$420,034 | 31 Mar 2025 |
| ORBIMED ADVISORS LLC |
13F
Company
|
117%
|
$1,305,249
1,787,767 shares
|
— | 31 Dec 2024 |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
Company
|
117%
|
$1,305,134
1,787,610 shares
|
— | 31 Dec 2024 |
| Ikarian Capital, LLC |
13F
Company
|
58%
|
$651,962
892,976 shares
|
— | 31 Dec 2024 |
| AIGH Capital Management LLC |
13F
Company
|
57%
|
$631,829
865,400 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
18
Shares
13,299,821
Rows available
18
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
16
Q1 2025 holders
18
Holder diff
2
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 value | Q1 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend